for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

United Therapeutics Corporation

UTHR.O

Latest Trade

82.14USD

Change

0.47(+0.58%)

Volume

517,308

Today's Range

80.60

 - 

82.78

52 Week Range

74.31

 - 

128.94

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
81.67
Open
81.43
Volume
517,308
3M AVG Volume
10.49
Today's High
82.78
Today's Low
80.60
52 Week High
128.94
52 Week Low
74.31
Shares Out (MIL)
43.85
Market Cap (MIL)
3,585.20
Forward P/E
-34.34
Dividend (Yield %)
--

Next Event

Q3 2019 United Therapeutics Corp Earnings Release

Latest Developments

More

Respira Therapeutics Regains North America Rights From United Therapeutics For Mid-Stage Drug Trial

United Therapeutics Announces FDA Acceptance Of Trevyent New Drug Application For Review

Ibio Inc Says It Entered Agreement With Unit Of United Therapeutics To Produce Recombinant Human Collagen-Based Bioink For 3D Bioprinted Organ Transplants

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About United Therapeutics Corporation

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). The Company markets and sells an oncology product in the United States, Unituxin (dinutuximab) Injection (Unituxin), which is approved for treatment of neuroblastoma. The Company is also engaged in early-stage research and development of a number of organ transplantation-related technologies.

Industry

Biotechnology & Drugs

Contact Info

1040 SPRING ST

+1.301.6089292

http://www.unither.com

Executive Leadership

Martine A. Rothblatt

Chairman of the Board, Chief Executive Officer

Michael Benkowitz

President, Chief Operating Officer

Christopher Patusky

Lead Independent Vice Chairman of the Board

James C. Edgemond

Chief Financial Officer, Treasurer

Paul A. Mahon

Executive Vice President, General Counsel, Corporate Secretary

Key Stats

2.40 mean rating - 10 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

1.6K

2017

1.7K

2018

1.6K

2019(E)

1.4K
EPS (USD)

2016

15.310

2017

9.310

2018

13.390

2019(E)

-2.314
Price To Earnings (TTM)
--
Price To Sales (TTM)
2.34
Price To Book (MRQ)
1.40
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
40.91
LT Debt To Equity (MRQ)
31.17
Return on Investment (TTM)
-3.78
Return on Equity (TTM)
-3.35

Latest News

Latest News

Arena Pharma soars on deal with United Therapeutics for hypertension drug

Shares of Arena Pharmaceuticals Inc jumped nearly 30 percent after the drug developer sold rights to develop and sell its hypertension treatment to United Therapeutics Corp, fetching it $800 million in an upfront payment.

BRIEF-United Therapeutics Reports Q1 Adj. Earnings Per Share Of $3.76

* Q1 EARNINGS PER SHARE VIEW $3.52 -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:

BRIEF-United Therapeutics To Acquire SteadyMed Ltd

* UNITED THERAPEUTICS-TRANSACTION, INCLUDING $75 MILLION IN CONTINGENT CONSIDERATION, IS VALUED AT $216 MILLION

BRIEF-United Therapeutics Says CEO Martine Rothblatt's FY 2017 Total Compensation Was $37.1 Mln

* UNITED THERAPEUTICS SAYS CEO MARTINE ROTHBLATT'S FY 2017 TOTAL COMPENSATION WAS $37.1 MILLION WHICH INCLUDED $33.1 MILLION IN OPTION/STAP AWARDS - SEC FILING

BRIEF-United Therapeutics Says FDA Accepted To Review Its NDA For Implantable System For Remodulin

* UNITED THERAPEUTICS- NOTIFIED BY FDA CO'S NDA FOR IMPLANTABLE SYSTEM FOR REMODULIN ACCEPTED FOR 6-MONTH REVIEW AS CLASS 2 RESUBMISSION - SEC FILING Source text: (https://bit.ly/2E6Hb6r) Further company coverage:

BRIEF-United Therapeutics Corp Reports Qtrly EPS Of $0.43

* Q4 EARNINGS PER SHARE VIEW $3.89, REVENUE VIEW $421.7 MILLION -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:

BRIEF-United Therapeutics Settles Patent Litigation With Actavis Laboratories FL

* UNITED THERAPEUTICS ANNOUNCES SETTLEMENT OF PATENT LITIGATION WITH ACTAVIS LABORATORIES FL, INC. RELATING TO ORENITRAM

BRIEF-Celularity Announces Formation Of Co With $250 Mln In Funding From Celgene, United Therapeutics, Others

* CELULARITY ANNOUNCES $250 MILLION IN FUNDING TO DELIVER TREATMENTS FOR CANCER, INFLAMMATORY AND DEGENERATIVE DISEASES, AND FUNCTIONAL REGENERATION

BRIEF-Corsair Pharma And United Therapeutics Enter Into Strategic Collaboration To Advance Novel Treprostinil Prodrugs

* CORSAIR PHARMA AND UNITED THERAPEUTICS ENTER INTO STRATEGIC COLLABORATION TO ADVANCE NOVEL TREPROSTINIL PRODRUGS

United Therapeutics to pay $210 million to resolve U.S. kickback probe

United Therapeutics Corp will pay $210 million to resolve U.S. claims that the drugmaker used a charity as a conduit to illegally cover Medicare patients' out-of-pocket drug costs in order to eliminate price sensitivity and to boost sales.

United Therapeutics to pay $210 mln to resolve U.S. kickback probe

United Therapeutics Corp will pay $210 million to resolve U.S. claims that the drugmaker used a charity as a conduit to illegally cover Medicare patients' out-of-pocket drug costs in order to eliminate price sensitivity and to boost sales.

BRIEF-STEADYMED RECEIVES FAVORABLE RULING FROM U.S. COURT OF APPEALS FOR THE FEDERAL CIRCUIT

* COURT OF APPEALS AFFIRMED A MARCH 31 RULING BY PATENT TRIAL & APPEAL BOARD INVALIDATING U.S. PATENT NO 8,497,393 OWNED BY UNITED THERAPEUTICS

BRIEF-United Therapeutics Corp reports third quarter 2017 financial results

* United Therapeutics Corporation reports third quarter 2017 financial results

BRIEF-United Therapeutics announces FDA approval of third generation nebulizer for the Tyvaso inhalation system

* United Therapeutics announces FDA approval of third generation nebulizer for the Tyvaso inhalation system

BRIEF-United Therapeutics Corp reports Q2 EPS non-GAAP $4.37

* United Therapeutics Corporation reports second quarter 2017 financial results

BRIEF-United Therapeutics enters into agreement with Citibank relating to share repurchase program

* United Therapeutics Corp - on May 31, 2017, co entered into agreement with Citibank, N.A. relating to a collared accelerated share repurchase program

BRIEF-United Therapeutics says it entered into first amendment to license agreement with Eli Lilly and company

* United Therapeutics Corp - on May 17, 2017, co entered into first amendment to license agreement with Eli Lilly and company

BRIEF-United Therapeutics announces $250 mln share repurchase program

* United Therapeutics announces $250 million share repurchase program

BRIEF-United Therapeutics and 3D Systems announce bioprinting agreement

* United therapeutics corp- 3d systems,united therapeutics today announced plans to develop solid-organ scaffolds for human transplants Source text for Eikon: Further company coverage:

BRIEF-Respira Therapeutics says entered into strategic collaboration with United Therapeutics

* Respira Therapeutics says entered into a strategic collaboration with united therapeutics corporation for development and exclusive license of respira's rt234

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up